Itron Insider Sold Shares Worth $425,210, According to a Recent SEC Filing-March 2024-www.financetom.com

Itron Insider Sold Shares Worth $425,210, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Itron Insider Sold Shares Worth $425,210, According to a Recent SEC Filing

Aug 29, 2024 8:24 AM

11:47 AM EDT, 08/23/2024 (MT Newswires) -- Donald L. Reeves III, Senior Vice President, Outcomes, on August 22, 2024, sold 4,210 shares in Itron ( ITRI ) for $425,210. Following the Form 4 filing with the SEC, Reeves has control over a total of 16,269 shares of the company, with 16,269 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/780571/000112760224022827/xslF345X05/form4.xml

Price: 102.00, Change: +1.81, Percent Change: +1.81

Previous page： Critical Mining Completes Initial Investment for Tanbreez Acquisition Next page： Patagonia Gold Advancing Permitting Process for Calcatreu Project in Argentina to "Final Stages of Approval"

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Critical Mining Completes Initial Investment for Tanbreez Acquisition

Jun 18, 2024

09:02 AM EDT, 06/18/2024 (MT Newswires) -- Critical Metals (CRML) said Tuesday that it has completed its initial investment as part of its plan to acquire Tanbreez, a rare-earth asset. In exchange for 5.55% of Tanbreez, Critical Metals has made an initial investment of $5 million to Rimbal, a company controlled by Gregory Barnes, who owns the Tanbreez project, Critical...

Patagonia Gold Advancing Permitting Process for Calcatreu Project in Argentina to "Final Stages of Approval"

Jun 18, 2024

09:02 AM EDT, 06/18/2024 (MT Newswires) -- Patagonia Gold ( HGLD ) said on Tuesday that the permitting process for the Calcatreu project in Argentina is now entering the final stages of approval. The company said the next step in the approval process is a review of the environmental impact report. Once a panel has issued its opinion, there will...

Jun 18, 2024

...

Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP

Jun 18, 2024

09:01 AM EDT, 06/18/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Tuesday that results of a phase 3 trial support the use of Hyqvia as maintenance treatment for chronic inflammatory demyelinating polyneuropathy or CIDP, an acquired, immune-mediated condition that affects the peripheral nervous system. Data showed Hyqvia's favorable long-term safety, tolerability and low relapse rate, the company said....